<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Higher plasma <z:chebi fb="0" ids="18405">pyridoxal 5'-phosphate</z:chebi> (PLP) levels are associated with a decreased incidence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but the influence of plasma PLP on survival of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is unknown </plain></SENT>
<SENT sid="1" pm="."><plain>We prospectively examined whether prediagnostic plasma PLP levels are associated with mortality among <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We included 472 incident cases of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> identified in the Nurses' Health Study, the Health Professionals Follow-up Study, and the Physicians' Health Study from 1984 to 2002 </plain></SENT>
<SENT sid="3" pm="."><plain>The patients provided blood samples two or more years before <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="4" pm="."><plain>Stratified Cox proportional hazards models were used to calculate hazard ratios (HR) with 95 % confidence intervals (CI) adjusted for other risk factors for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> survival </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Higher plasma PLP levels were not associated with a significant reduction in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific (169 <z:hpo ids='HP_0011420'>deaths</z:hpo>) or overall mortality (259 <z:hpo ids='HP_0011420'>deaths</z:hpo>) </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with patients who had less than 45 pmol/ml of plasma PLP (median: 33.6 pmol/ml), those who had 110 pmol/ml or higher levels (median: 158.8 pmol/ml) had multivariable HRs of 0.85 (95 % CI 0.50-1.45, p trend = 0.37) and 0.87 (95 % CI 0.56-1.35, p trend = 0.24) for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific and overall mortality </plain></SENT>
<SENT sid="7" pm="."><plain>Higher plasma PLP levels, however, seemed to be associated with better survival among patients who had lower circulating <z:chebi fb="0" ids="17933">25-hydroxyvitamin D3</z:chebi> levels (&lt;26.5 ng/ml) (p interaction ≤.005) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Higher prediagnostic plasma PLP levels were not associated with an improvement on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> survival overall </plain></SENT>
<SENT sid="9" pm="."><plain>Further research is needed to clarify the influence of <z:chebi fb="14" ids="27306">vitamin B6</z:chebi> on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> progression and survival </plain></SENT>
</text></document>